Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

F. Cicchiello, F. Riva, M. E. Cazzaniga, F. Pedani, M. Nicolini, C. Butti, N. Liscia, C. Pogliani, G. Capri, M. Alù, A. Febbraro, L. Petrucelli, L. D'Onofrio, D. Pellegrini, L. Mentuccia, V. Cocciolone, E. Miraglio, E. Bajardi, M. Dester, E. PaternòG. Guaitoli, I. Ferrarini, E. Gervasi, L. Licata, C. Benedetto, D. Andreis, E. Bordin, C. Ancona, L. Pizzuti, V. Fotia, R. Berardi, M. E. Cazzaniga, M. Airoldi, V. Arcangeli, S. Artale, F. Atzori, A. Ballerio, G. V. Bianchi, L. Blasi, S. Campidoglio, M. Ciccarese, M. C. Cursano, M. Piezzo, A. Fabi, L. Ferrari, A. Ferzi, C. Ficorella, A. Frassoldati, A. Fumagalli, on behalf of, The EVA Study Group

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study'. Together they form a unique fingerprint.

Medicine & Life Sciences